Sepsis and pancreatic cancer: Biliary stents a significant risk factor in patients undergoing chemotherapy. This is an ASCO Meeting Abstract from the 2021 Gastrointestinal Cancers Symposium. This ...
Effect of neoadjuvant therapy pathway (NATP) for pancreatic cancer on overall patient outcomes. This is an ASCO Meeting Abstract from the 2023 ASCO Gastrointestinal Cancers Symposium. This abstract ...
Pancreatic enzyme replacement therapy (PERT) successfully treats exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP), according to results of a meta-analysis of controlled ...
Pancreatic enzyme replacement therapy (PERT) is often an essential component of the treatment regimen for patients with pancreatic cancer, but it can be very pricey. "Out-of-pocket costs for a 30-day ...
A research study recently published in the American Journal of Gastroenterology explains the role of pancreatic enzyme therapy (PERT) in reducing the frequency of acute pancreatitis (AP) in children ...
Data were included from 13 unique prospective cohort screening studies reporting results for 1317 people. Data on nutritional markers (body mass index [BMI], albumin, total cholesterol) were collected ...
In a recent study posted to the medRxiv* preprint server, researchers evaluated the impact of the coronavirus disease 2019 (COVID-19) pandemic on the rates of pancreatic enzyme replacement therapy ...
Missing just one dose of your EPI medication can trigger gas, bloating, and stomach pain. These everyday strategies can help you remember to take PERT every time you eat. Despite our best efforts, it ...
Exocrine pancreatic insufficiency (EPI) develops when your pancreas doesn’t make or release enough digestive enzymes. This leaves undigested food in your intestines and causes gut pain, bloating, and ...
Patients with exocrine pancreatic insufficiency (EPI) have suboptimal secretion of pancreatic digestive enzymes and experience a range of clinical symptoms related to the malabsorption of fat. In ...
INDIANAPOLIS and CAMBRIDGE, Mass., July 2 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and Alnara Pharmaceuticals, Inc. today announced they have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback